A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University of Nebraska
National Institutes of Health Clinical Center (CC)
Merck Sharp & Dohme LLC
Travera Inc
University of Pittsburgh
PharmaMar
Instituto do Cancer do Estado de São Paulo
Travera Inc
Vastra Gotaland Region
Xencor, Inc.
Infinity Pharmaceuticals, Inc.
Stanford University
Precision Therapeutics